HDAC - Bladder Cancer - Prostate Cancer
Histone deacetylases (HDACs), known for their ability to target histones as well as more than 50 non-histone proteins, are classified into three major classes according to their homology to yeast proteins, including class I (HDAC1, HDAC2, HDAC3 and HDAC8), class II (HDAC4, HDAC5, HDAC7 and HDAC9) and class IV (HDAC11). HDAC inhibitors, a large group of compounds that is able to induce the accumulation of acetylated histones as well as non-histone proteins, are divided into several structural classes including hydroxamates, cyclic peptides, aliphatic acids and benzamides. HDAC inhibitors have been investigated for their efficacy as anticancer agents in the treatment of a wild range of cancers.
清除全部
- A4104 AR-42 (OSU-HDAC42)2 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC抑制剂
- A4096 Belinostat (PXD101)2 Citation中文名: 贝利司他Target: Histone Deacetylases (HDACs)Summary: 羟肟酸型HDAC抑制剂
- A4090 JNJ-264815853 CitationTarget: Histone Deacetylases (HDACs)Summary: HDAC抑制剂
- A4084 Vorinostat (SAHA, MK0683)9 Citation中文名: 伏立诺他Target: Histone Deacetylases (HDACs)Summary: HDAC抑制剂
- A8178 Panobinostat (LBH589)10 Citation中文名: 帕比司他Target: Histone Deacetylases (HDACs)Summary: HDAC抑制剂
- A8171 Entinostat (MS-275,SNDX-275)2 Citation中文名: 恩替诺特Target: Histone Deacetylases (HDACs)Summary: HDAC1和HDAC3抑制剂